Correlation of Dickkopf-1 with Inflammation in Crohn Disease.
Correlation of Dickkopf-1 with Inflammation in Crohn Disease. Indian Pediatr. 2019 Nov 15;56(11):929-932 Authors: Kim MJ, Choe YH Abstract OBJECTIVE: To explore the potential roles of Dickkopf-1 (DKK-1) and b-catenin in Crohn disease, and to evaluate the effects of a tumor necrosis factor (TNF)-a inhibitor on Wnt signaling in patients with the disease. METHODS: We enrolled 21 patients who received infliximab treatment for one year and achieved clinical remission during the treatment period. Disease activity was graded according to the Pediatric Crohn's Disease Activity Index (PCDAI). Peripheral blood and colonic mucosal specimens were collected from all patients with Crohn disease and from 14 healthy controls. DKK-1 levels in serum were detected by enzyme-linked immunosorbent assay (ELISA). Total RNA for DKK-1 and b-catenin from the frozen colonic tissue were obtained via real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR). Serum C-reactive protein (CRP) levels, erythrocyte sedimentation rates (ESR), and albumin were also measured in patients with Crohn disease before and after infliximab therapy. RESULTS: The serum levels of DKK-1 were significantly higher in patients with Crohn disease than in healthy controls (P=0.003) and were decreased in those treated with infliximab (P=0.026). Serum DKK-1 level was correlated with levels of ESR (r=0.527, P=0.025), CRP (r=0.502, P=0.034), albumin (r=0.363, P=0.021) and PCDAI (r...
We present the case of a 39-year-old male treated with Etanercept and debut of inflammatory bowel disease 11 months later. A literature review of the possible relationship between the debut and the treatment with Etanercept is done. PMID: 31793319 [PubMed - as supplied by publisher]
Conditions: Intestinal Disorder; Inflammatory Bowel Diseases; Crohn Disease Intervention: Other: acupuncture Sponsors: Shanghai Institute of Acupuncture, Moxibustion and Meridian; Fudan University; Shanghai University of Traditional Chinese Medicine; Shanghai Jiao Tong University School of Medicine; Indiana University School of Medicine Recruiting
ConclusionsIL-17 contributes to the pathogenesis of intestinal fibrosis, and anti-IL-17 therapy may weaken this effect by downregulating expression of profibrogenic cytokines and disturbing the MMP/TIMPs balance.
Drug therapies and the postoperative management of patients will be in the spotlight at the upcoming Advances in Inflammatory Bowel Diseases conference.Medscape Medical News
Conditions: Crohn Disease; Pediatric Crohns Disease Interventions: Drug: Azithromycin; Drug: Metronidazole; Other: Standard of Care Sponsors: University of North Carolina, Chapel Hill; Crohn's and Colitis Foundation; University of Amsterdam Not yet recruiting
Conclusions: The high prevalence of psychological disorders and malnutrition were found in IBD patients, and thereby negatively affect QoL. Disease activity was significantly associated with psychological disorders, risk of malnutrition and impaired QoL. And avoiding certain foods was related to risk of malnutrition. PMID: 31791216 [PubMed - as supplied by publisher]
Which endoscopic procedure best identifies neoplasia in patients with ulcerative colitis or Crohn disease?Alimentary Pharmacology &Therapeutics
Authors: Elosua González A, Sanz Segura P, Oyón Lara D, López García S, Arroyo Villarino MT, Alcalá Escriche MJ, Ollero Domenche L, Rodríguez Gutiérrez C, Nantes Castillejo Ó Abstract INTRODUCTION: CT-P13 is a biosimilar drug of infliximab (IFX), effective in patients with inflammatory bowel disease (IBD). The monitoring of levels of IFX and anti-IFX antibodies is now considered part of the integral management. OBJECTIVE: To compare the clinical response according to a strictly clinical (CLN) or proactive (PRO) approach based on the monitoring of levels in...
After receiving two chronic illness diagnosis by the age of 24, it really was no surprise that host Jackie Zimmerman also started to experience depression. Unable to tackle both, Jackie chose to focus on her physical health, letting her mental health deteriorate quickly — and dangerously. In this episode, we discuss the mind-body connection and how when your body is sick, your mind can quickly follow. (Transcript Available Below) SUBSCRIBE &REVIEW About The Not Crazy Podcast Hosts Gabe Howard is an award-winning writer and speaker who lives with bipolar disorder. He is the author of the popular bo...
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2)